GSK plc reported on September 12, 2024, positive results from a Phase II trial of its mRNA influenza vaccine, which showed immune responses against A and B strains in adults, meeting success criteria and advancing to Phase III.
AI Assistant
GSK PLC
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.